RT Book, Section
A1 Casteel, Kelly A.
A1 Kroll, Michael H.
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
A2 Rieber, Alyssa G.
SR Print(0)
ID 1190840223
T1 Cancer-Associated Thrombosis
T2 The MD Anderson Manual of Medical Oncology, 4e
YR 2022
FD 2022
PB McGraw Hill Education
PP New York, NY
SN 9781260467642
LK accessmedicine.mhmedical.com/content.aspx?aid=1190840223
RD 2024/04/18
AB KEY  CONCEPTSVenous  thromboembolism  (VTE)  is  common  in  patients  with  cancer  and  contributes  to  their  morbidity  and  mortality.All  hospitalized  patients  with  cancer  should  be  given  pharmacologic  thromboprophylaxis  unless  there  is  a  contraindication.High-risk  ambulatory  patients  with  cancer  receiving  outpatient  chemotherapy  can  be  considered  candidates  for  receiving  prophylactic-dose  apixaban  or  rivaroxaban.Cancer-associated  VTE  treatment  with  anticoagulation  is  associated  with  a  higher  rate  of  recurrence  and  bleeding  compared  with  non–cancer-related  VTE,  so  one  must  fastidiously  review  the  risk–benefit  ratio  for  each  patient  before  beginning  anticoagulation.Cancer-associated  thrombotic  microangiopathy  is  not  caused  by  ADAMTS-13  autoantibodies  and  does  not  improve  with  plasma  exchange.Routine  anticoagulation  or  antiplatelet  therapy  for  cancer  patients  with  atrial  fibrillation  or  coronary  artery  disease  appears  to  be  safe.